Simon P. Fletcher, Daniel J. Chin, Yongmei Ji, A. Leonardo Iniguez, Bruce Taillon, David C. Swinney, Palanikumar Ravindran, Donavan T. Cheng, Hans Bitter, Uri Lopatin, Han Ma, Klaus Klumpp, Stephan Menne – 20 March 2012 – The Eastern woodchuck (Marmota monax) is naturally infected with woodchuck hepatitis virus (WHV), a hepadnavirus closely related to the human hepatitis B virus (HBV).
Ragunath Singaravelu, Neda Nasheri, Allison Sherratt, John Paul Pezacki – 20 March 2012
Anna Mae Diehl – 20 March 2012
Junseong Park, Wonseok Kang, Seung‐Wook Ryu, Woo‐Il Kim, Dong‐Yeop Chang, Dong Ho Lee, Do Youn Park, Youn‐Hee Choi, Kyungsun Choi, Eui‐Cheol Shin, Chulhee Choi – 20 March 2012 – Hepatitis C virus (HCV) infection results in liver injury and long‐term complications, such as liver cirrhosis and hepatocellular carcinoma. Liver injury in HCV infection is believed to be caused by host immune responses, not by viral cytopathic effects. Tumor necrosis factor‐alpha (TNF‐α) plays a pivotal role in the inflammatory processes of hepatitis C.
Thuy‐Anh Le, Joshua Chen, Christopher Changchien, Michael R. Peterson, Yuko Kono, Heather Patton, Benjamin L. Cohen, David Brenner, Claude Sirlin, Rohit Loomba, for the San Diego Integrated NAFLD Research Consortium (SINC) – 20 March 2012 – Bile acid sequestrants (BAS) lower plasma low density lipoprotein levels and improve glycemic control. Colestimide, a BAS, has been claimed by computed tomography to reduce liver fat. Therefore, we examined the efficacy of colesevelam, a potent BAS, to decrease liver fat in patients with biopsy‐proven nonalcoholic steatohepatitis (NASH).
20 March 2012
Marina Berenguer, José‐Antonio Pons – 19 March 2012
John G. O'Grady – 19 March 2012
Matthew S. Chang, Sonja K. Olsen, Elsa M. Pichardo, Scott Heese, Jessica B. Stiles, Rita Abdelmessih, Elizabeth C. Verna, James V. Guarrera, Jean C. Emond, Robert S. Brown – 16 March 2012 – Lamivudine has been shown to prevent de novo hepatitis B virus (HBV) infections in liver transplantation (LT) patients receiving hepatitis B core antibody–positive (HBcAb+) grafts, but it may produce long‐term resistance. Adefovir dipivoxil (ADV) might be effective in preventing de novo hepatitis and resistance.